- Bluebird’s lovo-cel app finally lands in the FDA officeFiercePharma
- Bluebird submits sickle cell gene therapy to FDA for approvalSTAT
- bluebird bio submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for patients with sickle cell disease (SCD) 12 years and older with a history of vaso-occlusive eventsbusiness thread
- Bluebird bio submits U.S. marketing application for gene therapy for blood disordersReuters
- With FDA submission for sickle cell gene therapy, Bluebird Bio can potentially have 3 products approved by 2023Yahoo finance
- See full coverage on Google News